


Bispecific Antibody Products
Creative Biolabs is a specialized manufacturer of bispecific antibodies based on our advanced technology and years of experience. We are available to supply all kinds of bispecific antibodies that can be applicated in various research uses.
Bispecific antibodies are now being served as effective therapeutic agents in cancer immunotherapy. Certain recombinant strategies have been developed to synthesize bispecific antibodies, which include single chain variable fragment (scFv)-derived formats such as tandem diabodies, diabodies, BiIEs (bispecific immune cell engagers), and, as well as immunoglobulin G(IgG)-based formats such as two-in-one antibodies.
We offer a number of advanced strategies (recombinant DNA technology, phage display technology etc.) to synthesize the most comprehensive bispecific antibodies above-mentioned with high purity and affinity.
-
- Targets: EGFR & IGF-1R
- Type: Triplebody
- Application: FC, ELISA
-
- Targets: HER3 & ErbB-2
- Type: Bi-sdAb
- Application: PET-CT imaging
-
- Targets: EGFR & ErbB-3
- Type: Fab2
- Application: FC, ADCC Reporter Bioassay
-
- Targets: HER2 & VEGF
- Type: F(ab')2
- Application: FC
-
- Targets: EGFR & ErbB-2
- Type: IgG-IgG
- Application: ELISA
-
- Targets: DLL4 & VEGF
- Type: Bi-sdAb
- Application: ELISA
-
- Targets: D-DT & MIF
- Type: Fab2
- Application: ELISA
-
- Targets: CTLA4 & PD-1
- Type: Triplebody
- Application: FC
-
- Targets: MET & VEGFR-2
- Type: scFv2-Fc
- Application: FC
- Recombinant Anti-MET × Anti-VEGF IgG-IgG (MV10A) (BSIG-MZ001)
-
- Targets: MET & VEGF
- Type: IgG-IgG
- Application: ELISA
-
- Targets: MET & ErbB-3
- Type: Triplebody
- Application: Biacore assay, Cell proliferation assay
-
- Targets: MET & ErbB-2
- Type: Triplebody
- Application: WB, Confocal
-
- Targets: MET & EpCAM
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: MET & EGFR
- Type: Triplebody
- Application: FC
-
- Targets: MET & EGFR
- Type: Triplebody
- Application: WB, ICC
-
- Targets: CD30 & ErbB2
- Type: CrossMab
- Application: ELISA
-
- Targets: PAC1 receptor & CGRP receptor
- Type: CrossMab
- Application: ELISA
-
- Targets: CD45 & CD79
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: CD300A & IgE
- Type: Fab2
- Application: FC
-
- Targets: CD300A & IgE
- Type: Fab2
- Application: FC
-
- Targets: ROR1 & CD3
- Type: Fab2
- Application: FC
-
- Targets: ROR1 & CD3
- Type: CrossMab
- Application: FC
-
- Targets: ROR1 & CD3
- Type: Triplebody
- Application: FC
-
- Targets: PROM1 & CD3
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: IL5R & CD3
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: IL23R & CD3
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: MCSP & CD3
- Type: CrossMab
- Application: FC, ELISA
-
- Targets: GPC3 & CD3
- Type: DAF
- Application: FC, ELISA
-
- Targets: EGFRvIII & CD3
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: CD38 & CD3
- Type: Triplebody
- Application: SPR
-
- Targets: CD33 & CD3
- Type: Tandem Diabody
- Application: FC
-
- Targets: CD33 & CD3
- Type: Tandem Diabody
- Application: FC
-
- Targets: CD22 & CD79b
- Type: Tandem Diabody
- Application: FC
-
- Targets: CD19 & CD64
- Type: BsFab
-
- Targets: CD74 & CD22
- Type: BsFab
-
- Targets: EGFR & Fcgr1
- Type: CrossMab
-
- Targets: CEA & HSG
- Type: CrossMab
-
- Targets: Ang2 & VEGFA
- Type: CrossMab
-
- Targets: CD30 & CD16A
- Type: Tandem Diabody
-
- Targets: CD19 & CD3
- Type: Tandem Diabody
-
- Targets: FcγRIII & CD33 & CD19
- Type: Triplebody
- Application: FC
-
- Targets: phenyloxazolone(phOx) & hen egg lysosome(HEL)
- Type: Tandem Diabody
- Application: FuncS, Immunoassay
-
- Targets: EGFR & ZnO
- Type: Tandem Diabody
- Application: FuncS, Immunoassay
-
- Targets: C5 & HRPO
- Type: Tandem Diabody
- Application: FuncS, Immunoassay
-
- Targets: CD40 & Ad fiber knob
- Type: Tandem Diabody
- Application: FuncS, Gene delivery in gene therapy
-
- Targets: CEA & Ad fiber knob
- Type: Tandem Diabody
- Application: FuncS, Gene delivery in gene therapy
-
- Targets: TROP-2 & HSG
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: FN1 & HSG
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: FOLR1 & CD3
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: Thyroglobulin & TPO
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: S protein & pre S2 protein
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: CD28 & melanoma-associated proteoglycan
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: TCR(Vβ 8 ) & M2
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: FcγRI & LPA
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: FcγRIIB & LPA
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: EGFR & IGFR
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: FcγRIII & CD30
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: PLAP & CD3
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: EGFR & CD3
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: PDGFR2 & VEGFR2
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: Melanoma-associated proteoglycan & CD28
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: VEGFR2 & VEGFR3
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: EPCAM & CD3
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: CD33 & FcγRIII
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: VEGF & VEGF-B
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: Ang2 & VEGFA
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: NG2 & CD28
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: CD19 & CD47
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: CD20 & CD22
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: CD22 & CD19
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: DKKl & SOST
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: gpA33 & CD3
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: Myosin & CD45
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: CD47 & SIRPA
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: IL4 & IL13
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: EGFR & HER3
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: AR & DNA
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: VEGF & ANG2
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: IL-23 & IL-6
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: EGFR & HER2
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: CD20 & CD28
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: GD2 & FcγRIII
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: FcαRI & HLA class II
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: IGFR & HER3
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: HER2 & HER3
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: VEGF & PDGFRβ
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: IL-15 & TNFSF9
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: VEGF & FGF
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: EGFR & MET
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: IL-17A & IL-23
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: VEGF & OPN
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: IL17A & TNF
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: Betv1 & Feld1
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: PSCA & CD8
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: VEGF & HER2
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: HER1 & HER3
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: HER3 & EGFR
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: FXIa & FX
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: CD40 & CD28
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
-
- Targets: MET & EGFR
- Type: Tandem Diabody
- Application: FuncS, Promising therapeutic agent
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
For Research Use Only. Not For Clinical Use.